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Abstract
Background: Alterations in ceruloplasmin are currently assumed as one of the mechanisms
underlying the development of a number of neurodegenerative disorders. Several studies indicate
that elevated serum ceruloplasmin levels may play a role in schizophrenia by exacerbating or
perpetuating dopaminergic dysregulation. No study investigating the relationship between
ceruloplasmin and obsessive-compulsive disorder (OCD) has been published to date. Nowadays
OCD is increasingly speculated to be a different disorder than other anxiety disorders, and rather
is considered to be more similar to psychotic disorders. The objective of this study to explore
whether there is an association of ceruloplasmin with OCD as in schizophrenia.
Method: 26 pure OCD and 9 co-morbid OCD patients from Gaziantep University Sahinbey
Research Hospital, Psychiatry Clinics, diagnosed according to the DSM IV and 40 healthy controls
were included in the study. Blood samples were collected; ceruloplasmin levels were measured.
Results: The mean ceruloplasmin level in pure OCD patients, co-morbid OCD patients, and
control group persons were 544.46 ± 26.53, 424.43 ± 31.50 and 222.35 ± 8.88 U/L respectively.
Results of all 3 groups differ significantly. Positive predictive value of ceruloplasmin for that cut-off
point is 31/31 (100%) and negative predictive value is 40/44 (91%) in our group.
Conclusion: Although the nature of relationship is not clear there was an association between
ceruloplasmin levels and OCD in our study.
Background
Ceruloplasmin is a protein of the α2-globulin fraction of
human blood serum. It contains 95% of serum copper.
Hepatocytes synthesize ceruloplasmin, which is subse-
quently found in plasma, but extrahepatic gene expres-
sion has been documented for this protein. Among the
organs expressing ceruloplasmin gene are the brain, lung,
spleen, and testis. In the central nervous system of
humans and other mammals, ceruloplasmin is expressed
in neurons and astroglial cells, e.g., of the cerebral micro-
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vascular network. Ceruloplasmin carries copper from liver
to numerous tissues. The symptoms of Wilson's disease,
that is characterized by low levels of ceruloplasmin with
subsequent copper deposition in various tissues including
brain, often mimic those of schizophrenia. Ceruloplas-
min is also an iron oxidase; for this capacity, it has been
labeled ferroxidase I. In addition, ceruloplasmin is an
acute phase reactant, whose concentration increases in
inflammation, infection, trauma, etc. For these properties
it is known as an antioxidant. Ceruloplasmin has other
functions, including the oxidation of serotonin, epine-
phrine, and norepinephrine. The relation of ceruloplas-
min to neurodegenerative processes in human was
documented. Alterations in ceruloplasmin levels are cur-
rently regarded as one of the mechanisms underlying the
development of a number of neurodegenerative disor-
ders. Vassiliev et al. (2005) discussed largely ceruloplas-
min in neurodegenerative diseases [1].
There are numerous studies reporting an association
between ceruloplasmin and schizophrenia, but the nature
of the relationship remains unclear [2-9]. One possible
explanation has been ceruloplasmin and copper relation
since abnormalities in copper levels or metabolism may
lead to dopaminergic dysregulation. In addition, cerulo-
plasmin has been associated with some clinical features of
schizophrenia [2,4,5,8]. Some symptomatology of OCD
resembles to schizophrenia. Also dopaminergic dysregu-
lation in the certain areas of brain may play a role in OCD
etiopathogenesis as in schizophrenia [10,11]. Nowadays,
OCD is increasingly speculated to be a different disorder
than other anxiety disorders. OCD is rather thought to be
similar to psychotic disorders [12,13]. The objective of
this study is to explore, whether there is a role of cerulo-
plasmin in OCD as in schizophrenia. Therefore, we inves-
tigated the possible association between serum
ceruloplasmin levels and OCD. We have not identified
any study on this issue in the literature prior to our study.
Methods
Patients
37 consecutive OCD patients, who were diagnosed based
on DSM-IV (30 females, 7 males), and followed by
Department of Psychiatry, Gaziantep University Hospital
after they applied to Anxiety Disorders Unit, were enrolled
after they provided informed consent. The diagnoses of
OCD were established by one psychiatrist (SS). Nine of
the 37 patients had psychiatric comorbidities. In addition
to OCD, five of 9 suffered from other anxiety disorders, 2
from depression, 1 from schizoaffective disorder. The
remaining one patient had more than two psychiatric dis-
orders. Patients with comorbid diagnoses were included
in the study if the other psychiatric conditions were in
remission. Remission was defined as a score below or
equal to two ("borderline mentally ill") on Clinical Glo-
bal Impression (CGI)-Severity Scale [14]. All patients were
on their OCD treatment provided naturalistically by the
same psychiatrist. The data were collected within two
months. Exclusion criteria were as follows: alcohol or sub-
stance dependence according to the DSM-IV, tardive dys-
kinesia related to neuroleptics, presence of severe organic
condition, use of any antioxidant agent (i.e. vitamins E
and C), presence of epilepsy or other severe neurological
disorder which were previously found to be associated
with oxidative status, presence of infectious disease, exces-
sive obesity and insufficient sampling. Two patients were
excluded due to insufficient sampling.
Controls
The control group consisted of forty healthy volunteers
who were recruited from university staff (30 females, 10
males). They were free of any medication for at least 6
weeks prior to blood sampling. None of the control sub-
jects were alcohol consumer, heavy smoker, or had ever
taken any psychotropic drugs. They had no history or fam-
ily history of any psychiatric disorder. The controls were
matched with the patients in regards to sex and age. All
subjects signed written informed consent, which had been
approved by the local ethics committee in accordance
with the Declaration of Helsinki. Physical and neurologi-
cal examinations were performed on each of the patients
and controls. Only subjects with normal physical and
neurological exams and without any exclusion criteria
were admitted to the study.
Instruments
Sociodemographic information form
All subjects were evaluated by a semi-structured question-
naire, which was developed in accordance with clinical
criteria and available information sources. Gender, age,
marital status, smoking habits, socioeconomic status, and
duration of illness were recorded before venous blood
sampling.
Yale-Brown Obsession Compulsion Scale
Yale-Brown Obsession Compulsion Scale in Turkish (Y-
BOCS) is a scale that assesses the severity of OCD without
focusing on the contents of obsession and compulsion
[15]. It has ten items. Each item is assessed between 0 and
4 points by a clinician. Patients were rated by the same
psychiatrist (SS) twice, on the venous sampling day for
initial Y-BOCS evaluation and after two months for late Y-
BOCS scores. During second evaluation the rater was
blinded to the serum measures.
Blood sampling
Venous blood samples from left forearm vein were col-
lected into 5 ml vacutainer tubes between 7 and 8 a.m.
after overnight fasting. The blood samples were centri-
fuged at 2000 rpm for 10 min to obtain sera. SamplesBehavioral and Brain Functions 2008, 4:52 http://www.behavioralandbrainfunctions.com/content/4/1/52
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were stored frozen at -40°C before analysis. The biochem-
ical analyses were made after all the blood samples were
collected.
Ceruloplasmin measurement
Erel's ceruloplasmin measurement method is used. This
method is automated, colorimetric, and based on the
enzymatic oxidation of ferrous ion to ferric ion [16]. The
results were expressed in milligrams per deciliter, and the
precision of this assay is within 3%. For a details see Erel
[16,17].
Apparatus
A Cecil 3000 spectrophotometer with a temperature con-
trolled cuvette holder (Cecil) and an Aeroset automated
analyzer (Abbott) were used [16].
Statistical Analysis
The obtained data were evaluated by SPSS for Windows
13.0. The comparisons were performed by ANOVA with
Tukey HSD (for two-group and all-group comparisons).
For correlation evaluations, the Spearman correlation
(two-tailed) was used. The comparison of sociodemo-
graphic characteristics was performed by the independent
samples T test. Two-tailed forms were used. The compari-
son of serum levels among groups was performed by Post
Hoc Tukey's Test and Dunnett's Test. The statistical signif-
icance was accepted as p < 0.05. Using receiver operating
characteristic (ROC) analysis, curve was plotted of sensi-
tivity versus 1 minus specificity for all possible cut-off
scores of serum ceruloplasmin level as a diagnostic test.
The accuracy of the serum ceruloplasmin level as a diag-
nostic test in OCD is represented by, and is directly pro-
portional to, the area under the curve (AUC).
Results
The demographic and clinical data of the subjects were
summarized in Table 1. The mean ceruloplasmin levels in
pure OCD patients, co-morbid OCD patients and control
group persons were 544.46 ± 26.53, 424.43 ± 31.50 and
222.35 ± 8.88 U/L respectively. The mean ceruloplasmin
levels were significantly higher in pure and co-morbid
OCD groups than that of control group (p < 0.01). In pure
OCD group mean ceruloplasmin level was significantly
higher than co-morbid OCD group (p < 0.01). In plotted
ROC curve (Figure 1) OCD could be predicted for cerulo-
plasmin over 342.85 U/L level with 88.6% sensitivity and
100% specificity (Table 2). Positive predictive value of cer-
uloplasmin for that cut-off point was 31/31 (100%) and
negative predictive value was 40/44 (91%) in our study.
There was no correlation between ceruloplasmin and ill-
ness duration or YBOCS scores (p > 0.05).
Discussion
The association between ceruloplasmin and OCD has not
been investigated so far. To the best of our knowledge this
is the first report about elevated ceruloplasmin levels in
OCD patients. Ceruloplasmin abnormalities have been
implicated in schizophrenia, even the nature of relation-
ship remains unclear. Since abnormalities in copper
metabolism may lead to dopaminergic dysregulation, the
ceruloplasmin and copper relationship might be impor-
tant in schizophrenia [9]. Ceruloplasmin largely deter-
mines copper concentration, and plays a critical role in
the interpretation of copper results [18,19]. One sug-
gested strategy to study copper is to measure ceruloplas-
min levels, because approximately 95% of the copper in
blood is bound to ceruloplasmin, therefore increases in
ceruloplasmin would be expected to correlate directly
with increases in serum copper. Both increased serum
copper and ceruloplasmin levels have been found in the
same schizophrenic patients [9]. The importance of
dopamine has been largely studied in schizophrenia and
copper plays role in the synthesis and metabolism path-
ways of dopamine. For example, the copper-dependent
enzyme tyrosinase shunts tyrosine away from DOPA pro-
duction, copper inhibits dopa-decarboxylase thereby
inhibiting dopamine production, the copper-dependent
enzyme dopamine beta-hydroxylase catalyzes the break-
down of dopamine into norepinephrine, and the copper-
dependent enzyme monoamine oxidase (MAO) catalyzes
the breakdown of dopamine into other metabolites. Ele-
vated copper and corresponding changes in dopamine
may result in increased number or sensitivity of post-syn-
aptic dopamine receptors in certain areas of the brain.
Thus, elevated ceruloplasmin results in increased copper,
which may lead to psychotic symptoms through the men-
tioned mechanism. Similarly, psychotic symptoms occur
in Wilson's disease, in which there is copper deposition in
liver, cornea, and brain due to lack of ceruloplasmin. This
leads to over exposure of brain to copper [9,20].
As in schizophrenia, association between ceruloplasmin
and OCD might be examined through ceruloplasmin and
copper relationship, since there is now growing evidence
that the dopamine system may be involved also in the
pathophysiology of OCD [21-23]. An association
between OCD and increased midbrain dopamine neuro-
transmission has been reported. In addition, atypical
antipsychotics, such as risperidone and quetiapine, may
augment the response to selective serotonin reuptake
inhibitors (SSRIs) in patients with refractory OCD. This
would seem to point to an increase in dopaminergic sys-
tem activity in OCD [24,25]. As in schizophrenia
increased ceruloplasmin levels may increase copper levels,
which may lead to dopaminergic dysregulation in OCD.Behavioral and Brain Functions 2008, 4:52 http://www.behavioralandbrainfunctions.com/content/4/1/52
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In plotted ROC curve, disease condition (OCD) can be predicted via ceruloplasmin levels over 342 Figure 1
In plotted ROC curve, disease condition (OCD) can be predicted via ceruloplasmin levels over 342.85 U/L with 
88.6% sensitivity and 100% specificity.Behavioral and Brain Functions 2008, 4:52 http://www.behavioralandbrainfunctions.com/content/4/1/52
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However, association between ceruloplasmin and OCD
may be explained via copper and serotonin relationship,
too. Copper induces oxidation of serotonin and the prod-
ucts of 5-HT oxidation are or have the potential to be neu-
rotoxic, especially on serotonergic receptors. Copper
structurally alters serotonin by effectively converting func-
tional 5-HT into dimeric species. It has been suggested
that this process might play a role in copper related neu-
rodegenerative diseases [26].
An intriguing link between copper and 5-HT is suggested
by symptoms observed in a number of diseases, for
instance, in patients with Wilson's disease depression,
anxiety, personality changes, and cognitive impairment
are among the common symptoms, and a number of
studies indicate that disruption of the serotonergic system
may partly explain these changes [27,28]. It is well known
that serotonin has been implicated in the neurobiology
OCD. It has been suggested that OCD might be related to
the functioning of brain serotonin systems. This hypothe-
sis is based largely on the notion that SSRIs possess
antiobsessional efficacy [29-31]. Neuroimaging studies
have been very influential in shaping neurobiological
models of OCD. Converging data have implicated a net-
work of brain regions, including the orbitofrontal cortex,
striatum, and thalamus, in the pathophysiology of OCD.
Most regions of the putatively involved network in OCD
are densely innervated by serotonergic or dopaminergic
neurons [32]. Also, in animal models and preclinical stud-
ies significant interactions between serotonergic and
dopaminergic systems in OCD have been reported
[33,34].
On the other hand, some in vitro studies have demon-
strated that ceruloplasmin is a potent antioxidant, even
more potent than albumin and superoxide dismutase
[35]. Previous studies suggested an oxidative imbalance in
OCD. Selek et al. (2008) reported that total antioxidant
status might be increased reactively in OCD [36].
Interestingly, in our study pure OCD patients had a higher
mean level of ceruloplasmin than comorbid OCD
patients, thus pointing out a more relevant situation
between OCD and other disorders. In some schizophre-
nia studies, plasma ceruloplasmin was associated with
subtypes, duration, severity, and antipsychotic treatment
of schizophrenia. [3-5,8]. We did not find any association
between ceruloplasmin and duration of illness or Y-
BOCS-scores of OCD.
Another finding is with a cut-off point of 342.85 U/L cer-
uloplasmin levels OCD can be predicted in our group. The
positive predictive value was 100% and negative predic-
tive value was 91%.
Some limitations of this study include: Sample size is rel-
atively small, not all of the patients have pure OCD, some
of them have co-morbid psychiatric disorders, and all
patients were receiving drug therapy. The ongoing drug
treatments were not interrupted due to ethical considera-
tions.
Conclusion
To the best of our knowledge, this is the first study about
plasma ceruloplasmin in OCD. Although we found that
plasma ceruloplasmin was higher in OCD than healthy
controls, the role of ceruloplasmin in OCD remains
Table 1: Sociodemographic and clinical characteristics of 
patients
All Patients Pure OCD
Sex: female/male (n) 28/7 22/4
Age: Mean ± SD 33.4 ± 11.2 34.5 ± 11.0
Illness duration (years): Median 5 (1–30) 5 (1–30)
YBOCS-initial: Mean ± SD 9.8 ± 5.7 9.7 ± 5.8
YBOCS-later: Mean ± SD 9.2 ± 5.9 8.5 ± 6.0
Table 2: Characteristics and coordinates of ROC Curve
Variable Area under Curve P value 95% Confidence Interval
Lower Bound Upper Bound
Ceruloplasmin 0.989 < 0.001 0.971 1.006
Coordinates of ROC curve
Variable Positive if greater or equal to Sensitivity Specificity
Ceruloplasmin 327.8500 0.914 0.025
332.3500 0.886 0.025
342.8500 0.857 0.000
362.2500 0.829 0.000
376.9500 0.792 0.000Behavioral and Brain Functions 2008, 4:52 http://www.behavioralandbrainfunctions.com/content/4/1/52
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unclear. Our results suggest that alterations in ceruloplas-
min levels may reflect a response to illness that serves as
some kind of non specific protective mechanism or dura-
tion effect of the illness or drug therapy. Further research
is warranted to replicate our findings and also to study fur-
ther the relationship between ceruloplasmin and OCD.
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